B. Riley Issues Pessimistic Forecast for Harrow (NASDAQ:HROW) Stock Price

Harrow (NASDAQ:HROW) had its price objective decreased by research analysts at B. Riley from $69.00 to $65.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley’s target price would indicate a potential upside of 157.58% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $57.00 target price on shares of Harrow in a research report on Monday.

Harrow Trading Down 5.1 %

Shares of Harrow stock traded down $1.37 on Tuesday, hitting $25.24. 457,556 shares of the company traded hands, compared to its average volume of 498,638. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market cap of $898.74 million, a PE ratio of -26.84 and a beta of 0.69. The stock’s 50 day moving average price is $28.76 and its 200-day moving average price is $37.86. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. The firm had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Equities research analysts predict that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

Several hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new position in shares of Harrow in the 3rd quarter valued at about $460,000. Charles Schwab Investment Management Inc. increased its position in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after buying an additional 166,602 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Harrow during the 3rd quarter worth approximately $549,000. FMR LLC lifted its position in shares of Harrow by 521.6% during the 3rd quarter. FMR LLC now owns 11,034 shares of the company’s stock valued at $496,000 after buying an additional 9,259 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Harrow by 3,015.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 79,974 shares of the company’s stock valued at $3,596,000 after acquiring an additional 77,407 shares during the period. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.